10033 - Melanoma Diagnosis: Current State of the Art with Update on Molecular Diagnostics

Course Director

Steven R. Tahan, M.D., Harvard Medical School


This course reviews the current status of tissue diagnosis of melanoma, including a review of the light microscopic criteria for diagnosis and prognosis, and identification of problem areas that would benefit from adjunct molecular testing. It reviews the development, principles, and limitations of applying fluorescence in-situ hybridization to melanoma diagnosis, reviews the evolving discipline of genomic mutational analysis for identifying specific targets for personalized therapies, and suggests need areas in melanoma tissue diagnosis today and in near future.


AMA PRA Category 1 Credits™

Opus Medicus designates this Internet enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC) Credits

In addition to AMA PRA Category 1 Credits™, Opus Medicus designates this course for Specialty Board MOC Program Credits:

1.25 ABP SAM for MOC/CC Credits1

Accreditation Statement

Opus Medicus is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Tuition Fees

Course & Credits: $32.50

Course Dates

Last Review Date: 10-Aug-2019
Expiration Date: 09-Aug-2022


The course objectives are for Pathologists, Oncologists, Dermatologists, and trainees to review:

1. Current state of the art for melanoma diagnosis (H&E, Immunohistochemistry)

2. Problematic, controversial, and borderline lesion areas.

3. 4-probe FISH assay for diagnosis

4. Prognosis assessment

5. Diagnostic tests for specific molecular targets (BRAF, c-KIT)

6. Molecular diagnostic testing for today and near future.


1. Perspectives on melanoma in U.S.

2. Current Gold Standard for Histologic Diagnosis and Prognosis Assessmeent

3. Identification of Problem areas for Diagnosis.

4. Fluorescence in-situ Hybridization (FISH) - Development, applications, and limitations.

5. Assessment of Prognosis

6. Therapeutic Targets: BRAF and C-KIT.

7. Immune modulation.

8. Molecular diagnostic tests needed today and near future.

Specific topics covered in this AMA PRA Categogy 1 Credit™ online CME course include malignant melanoma, melanoma, fluorescence in-situ hybridization, FISH, melanoma diagnosis, melanoma prognosis assessment, perineural invasion, lympho-vascular invasion, P75NGFR, D2-40, BRAF mutation, C-Kit mutation, molecular diagnostics, and molecular pathology.

American Board of Medical Specialties (ABMS) / Accreditation Council for Graduate Medical Education (ACGME) Competencies

☑  Patient Care (PC)
☑  Medical Knowledge (MK)
☑  Practice-Based Learning (PBL)

Financial Relationship Disclosure and Content Attestation

Dr. Steven R. Tahan serves on an Advisory Committee in Dermatopathology for Myriad Genetics of Salt Lake City, Utah, which has had no influence on any aspect of this course. No other person who has provided content for or who can influence the content of this course has disclosed financial relationships with commercial entities that produce healthcare-related products or services relevant to the course content.

There has been no commercial support for this course.

Supported Computer Hardware and Software Configurations2

Supported client computing platforms include:

A broadband Internet connection is required (e.g., cable, DSL, and 3G or 4G wireless). The course presentation is automatically scaled to the size of the display, from 800x480 pixels (minimum supported) to 1920x1200 pixels. On some smart phones, viewing courses may be tedious.

Supported browsers include:

Javascript, cookies, and popups must be enabled on your browser (which is the default configuration for most browsers).

1. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Self Assessment Module (SAM) Credits in the American Board of Pathology (ABP) Maintenance of Certification (MOC) / Continuing Certification (CC) Program, in addition to AMA PRA Category 1 Credits™. Participants will earn SAM for MOC/CC credits equivalent to the amount of AMA PRA Category 1 credits claimed for the activity. Immediately upon course completion, Opus Medicus will submit participant completion information to ACCME for the purpose of granting ABP MOC/CC credit.

2. The course may also be viewable on other client computing platforms that comply with Internet standards. If you experience technical problems that prevent you from viewing the course, we will promptly issue a full refund upon request.